Metadata record for the manuscript: OMO-1 reduces tumor progression and enhances cisplatin efficacy in a 4T1-based non c-MET addicted intraductal mouse model for triple-negative breast cancer

<b>Summary</b> This metadata record provides details of the data supporting the claims of the related manuscript: “OMO-1 reduces tumor progression and enhances cisplatin efficacy in a 4T1-based non c-MET addicted intraductal mouse model for triple-negative breast cancer ”. The related study investigated the therapeutic efficacy of OMO-1, a potent and selective c-MET inhibitor, in an immunocompetent intraductal mouse model for triple-negative breast cancer (TNBC). Type of data: Histology and immunohisto/cytochemistry, spreadsheets, western blot analysis Subject of data: 4T1 cell culture, BALB/c mice Sample size: 4 mice <b>Data access</b> The histology and immunohisto/cytochemistry, spreadsheets and western blot analysis data are not publicly available for the following reason: a patent application on OMO-1 in non c-MET addicted tumours is still pending. However, the data can be made available upon reasonable request to the corresponding author. A comprehensive list of the datafiles underlying each of the figures and supplementary figures in the related manuscript is shared together with this metadata record in the file ‘Steenbrugge_et_al_2021_data_underlying_figures.xlsx’. <b>Corresponding author(s) for this study</b> Jonas Steenbrugge, Laboratory of Biochemistry, Department of Pharmacology, Toxicology and Biochemistry, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium. e-mail: [e-mail]. <br> <b>Study approval </b> The Ethical Committee (EC) of the Faculty of Veterinary Medicine, Ghent University (EC 2018-37 and amendment EC 2018-65).